Interview https://www.benzinga.com/views/taxonomy/term/125566 en SoFi's Former Head Of Venture Strikes Out On His Own https://www.benzinga.com/markets/cryptocurrency/18/09/12373843/sofis-former-head-of-venture-strikes-out-on-his-own <p><em>The <a href="https://benzingafintechsummit.com/">Benzinga Fintech Summit</a> is a gathering of the top leaders in payments, lending, capital markets, blockchain and cryptocurrencies in San Francisco Nov. 14. Ahead of the Summit, Benzinga is profiling the fintech thought leaders speaking at the event.</em></p> <p>For this installment, Benzinga interviewed an intriguing fintech venture capitalist: Logan Allin, general partner at Fin Venture Capital and former head of venture at SoFi.</p> <p>Allin&#39;s career has been largely spent &quot;in and around&quot; financial services, he said, including stints&nbsp;at SoFi, City National Bank and <strong>Invesco Ltd. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ivz#NYSE">IVZ</a>). He launched Fin Venture Capital in April with a focus on the <a href="https://www.benzinga.com/topic/fintech">global fintech sector</a>,&nbsp;greenfield areas and B2B and B2B2C players in particular.&nbsp;</p> <p><strong>BZ: What trend in fintech are you paying the most attention to right now?</strong></p> <p>In fintech, there are six subsectors we believe still have white space and room for growth and outperformance:&nbsp;</p> <ul> <li>Alternative finance and lending, particularly in middle market and commercial.</li> <li>Asset management.</li> <li>Real estate tech.&nbsp;</li> <li>Insurtech.&nbsp;</li> <li>Blockchain enterprise applications.&nbsp;</li> <li>Enabling tech such as AI, machine and deep learning, big data and analytics, cybersecurity, biometrics and other infrastructure.</li> </ul> <p>Three key investment themes are fundamental to success in this space:&nbsp;</p> <ul> <li>Proprietary networks and access to geographic and company ecosystems, both direct and spin-outs,&nbsp;are fundamental to company quality and selection in fintech.&nbsp;</li> <li>We are experiencing a &ldquo;re-coupling&rdquo; in fintech, and true platform players &mdash; multiproduct and omnichannel &mdash;&nbsp;will continue to outperform and consolidate single vertical players.</li> <li>&ldquo;Disruptors&rdquo; and those disintermediating large incumbent tech or finserv companies will dominate &ldquo;augmenters&rdquo; without sufficient scale, TAM&nbsp;or unit economics.</li> </ul> <p><strong>BZ: Fintech funding rounds are getting larger, some consolidation is occurring&nbsp;and the space in general is maturing &mdash; is there still room for small startups to have a major impact? What verticals are ripe for disruption?</strong></p> <p>According to Pitchbook&rsquo;s data, the&nbsp;U.S. funding environment is skewed increasingly to growth and late stage startups and is on pace to surpass $100 billion in deal value for the first time since the dot-com era.</p> <p>Indeed, there was $57.5 ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/18/09/12373843/sofis-former-head-of-venture-strikes-out-on-his-own alt=SoFi&#039;s Former Head Of Venture Strikes Out On His Own>Full story available on Benzinga.com</a></p> City National Bank Cryptocurrency Fin Venture Capital Fintech IVZ SoFi Markets Interview IVZ BMG491BT1088 Cryptocurrency Fintech Markets Interview Benzinga Tue, 18 Sep 2018 22:09:28 +0000 Spencer White 12373843 at https://www.benzinga.com The Crypto Hedge Fund Founder Backed By Steve Cohen Looks Ahead https://www.benzinga.com/markets/cryptocurrency/18/09/12366559/the-crypto-hedge-fund-founder-backed-by-steve-cohen-looks-ahea <p><em>The <a href="https://benzingafintechsummit.com/">Benzinga Fintech Summit</a> is a gathering of the top leaders in payments, lending, capital markets, blockchain and cryptocurrencies in San Francisco Nov. 14. Ahead of the Summit, Benzinga is profiling the fintech thought leaders speaking at the event.</em></p> <p>Our next installment is an interview with Arianna Simpson, founder of Autonomous Partners, a cryptocurrency- and blockchain-focused hedge fund that recently received major backing from investing giant Steve Cohen and Coinbase CEO Brian Armstrong.</p> <p><strong>BZ: What is Autonomous Partners, and what is its investment thesis?&nbsp;</strong></p> <p>Autonomous Partners is a fund investing in cryptocurrencies, digital assets&nbsp;and blockchain-based companies. We take a very long-term approach and generally invest in things we plan to hold for periods of years &mdash; even when shorter-term liquidity is available. Great technology takes time to build, so we have a bias toward patience.&nbsp;</p> <p><strong>BZ: Why are key investors like Union Square and Steve Cohen and crypto pioneers like Brian Armstrong excited about what you&#39;re doing? What value do these investors bring to the company beyond funding?</strong></p> <p>I guess you&#39;d have to ask them, but my sense is that my long involvement in the space, and the deep relationships I&#39;ve built over the past five years working in the industry has something to do with it. I have had a longstanding interest in crypto and combining that with the ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/18/09/12366559/the-crypto-hedge-fund-founder-backed-by-steve-cohen-looks-ahea alt=The Crypto Hedge Fund Founder Backed By Steve Cohen Looks Ahead>Full story available on Benzinga.com</a></p> Arianna Simpson Autonomous Partners Benzinga Fintech Summit Brian Armstrong Cryptocurrency Fintech Steve Cohen Union Square Hedge Funds Top Stories Markets Interview General Cryptocurrency Fintech Hedge Funds Top Stories Markets Interview General Benzinga Mon, 17 Sep 2018 21:35:54 +0000 Spencer White 12366559 at https://www.benzinga.com Cannabis Investment Fund Breaks Down Its 7 Latest Picks https://www.benzinga.com/markets/cannabis/18/09/12352349/cannabis-investment-fund-breaks-down-its-7-latest-picks <p>Money is flowing into the <a href="https://www.benzinga.com/topic/cannabis">cannabis industry</a> at an unprecedented pace. And it&rsquo;s not just the&nbsp;<strong>Canopy Growth Corp&nbsp;</strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) and&nbsp;<strong>Cronos Group Inc&nbsp;</strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>)&rsquo;s of the world on the receiving end: public and private companies across the spectrum are drawing&nbsp;considerable investor attention.</p> <p>Cannabis investments surpassed $5.6 billion as of Sept. 7, according to Viridian Capital Advisors&#39; cannabis deal tracker.&nbsp;</p> <p>While we know who&rsquo;s investing, it&#39;s rare for&nbsp;funds to explain&nbsp;<em>why</em>&nbsp;they chose certain companies over others. Fortunately,&nbsp;<strong>Altitude Investment Management&nbsp;</strong>were willing to let us in on some of their secrets, offering to walk Benzinga&nbsp;through the&nbsp;latest additions to their Altitude Investment Partners, LP fund.</p> <h3>10 Investments, 6 Months</h3> <p>From March to August of this year,&nbsp;Altitude&rsquo;s fund invested in 10&nbsp;companies. Six were add-on investments to existing portfolio companies; four others were investments in companies new to the Altitude portfolio, which now consists of 15 company stakes.&nbsp;</p> <p>The fund made an add-on investment as co-lead in&nbsp;<strong>BDS Analytics&rsquo;</strong>&nbsp;Series B preferred stock $3.5-million capital raise.</p> <p>BDS is one of the leaders in cannabis business intelligence. This funding places BDS in a strong position to execute ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12352349/cannabis-investment-fund-breaks-down-its-7-latest-picks alt=Cannabis Investment Fund Breaks Down Its 7 Latest Picks>Full story available on Benzinga.com</a></p> AES Compassionate Care Altitude Investment Management BDS Analytics best marijuana stocks Canabis Cannabis cannabis news cannabis stocks Canndescent CGC CRON Flowhub Ganja Golden Systems Grassroots Compass Ventures HMLSF invest in marijuana John Brecker Jon Trauben legal marijuana legal weed marihuana marijuana marijuana legalize marijuana news marijuana stocks marijuanas stock med marijuana medical medical cannabis medical marijuana medical marijuana stock medicinal marijuana Michael Goldberg MJ News PathogenDx pot Recreational Marijuana Rod Stephan THC Viridian Capital Advisors weed weed stock Financing Markets Interview General CGC MJ HMLSF CRON News Cannabis Financing Markets Interview General Benzinga Sat, 15 Sep 2018 16:41:13 +0000 Javier Hasse 12352349 at https://www.benzinga.com Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/markets/cannabis/18/09/12358350/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we <p>The cannabis sector was&nbsp;mostly dominated by non-financial events this week &mdash; namely, an ongoing&nbsp;freak out over <strong>Tesla Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>)&rsquo;s Elon Musk taking <a href="https://www.benzinga.com/markets/cannabis/18/09/12321478/elon-musk-creates-a-buzz-with-joe-rogan-interview"><em>one </em>puff </a>of a blunt during his appearance on &ldquo;The Joe Rogan Experience.&rdquo;</p> <p>Another big news item:&nbsp;a <a href="https://www.greenentrepreneur.com/article/319964" style="color:blue; text-decoration:underline">report released</a> by the&nbsp;<strong>Brightfield Group.&nbsp;</strong>According to analysts at the firm, sales in the hemp-derived CBD market will hit $22 billion by 2022 in the U.S. alone. This means that, as Benzinga argued in an article more than a year ago, hemp could prove a <a href="https://www.benzinga.com/trading-ideas/long-ideas/17/08/9909654/why-industrial-hemp-could-prove-a-larger-economic-driver-than" style="color:blue; text-decoration:underline">larger economic driver</a> than marijuana; <a href="https://mjbizdaily.com/exclusive-marijuana-sales-may-reach-10-billion-this-year-22-billion-by-2022/" style="color:blue; text-decoration:underline">estimates</a> out of MJBizDaily establish $22 billion as the higher end of the spectrum for cannabis sales in 2022.</p> <p>Also quite notable was an article posted Thursday on <strong>Politico,</strong> quoting &ldquo;a senior official overseeing U.S border operations,&rdquo; Todd Owen, who explained how and why Canadians who use marijuana, work in the industry or even invest in it, face a potential lifetime ban by the U.S. when trying to cross the border.</p> <p>&ldquo;Technically speaking, this has always been an issue, yet was rarely enforced,&rdquo; said Jeff Siegel, managing editor of Green Chip Stocks and a Benzinga cannabis <a href="https://www.benzinga.com/author/jeff-siegel" style="color:blue; text-decoration:underline">writer</a>. &ldquo;Some have suggested that because Canada is about to legalize, someone at U.S. Customs and Border Protection decided to chest-pound this in the form of a veiled threat, which of course begs the question: who initiated it?&quot;</p> <p>Siegel speculated that the statement was instigated by Department of Justice or White House Officials and could have been used as leverage in trade talks.&nbsp;</p> <p>&ldquo;I don&rsquo;t actually expect most agents to go out of their way to enforce this though, as such a thing is quite trivial and not worth their time. Catching terrorists is further up on the &lsquo;to-do&rsquo; list compared to busting bean counters and CFOs of cannabis companies entering the U.S. to speak at conferences or work with investors who still want a piece of the Canadian cannabis market.&quot;</p> <p>The idea that cannabis stocks tanked Thursday as a result of the Politico story is &quot;ridiculous,&quot; Siegel said.&nbsp;</p> <p>&quot;The entire market is insanely overvalued and desperately needs to sell off. Perhaps this added to the jitters of those who know this market is top-heavy, but to say that the market sold off solely because this border patrol story is a bit of a reach.&rdquo;</p> <p>Check out more reactions from industry insiders and stock moves resulting from the news in this Benzinga <a href="https://www.benzinga.com/markets/cannabis/18/09/12357475/canadians-in-marijuana-biz-could-face-lifetime-us-travel-ban-what-in#/null" style="color:blue; text-decoration:underline">story</a>.</p> <h3>Marijuana Indexes &amp; ETFs</h3> <p>The <strong>United States Marijuana Index, </strong>which tracks 18 of the largest marijuana stocks in the U.S., gained roughly 4.5 percent this week, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, ended the week up 1.9 percent, despite experiencing a big tumble&nbsp;Thursday and Friday.</p> <p>Over the last five trading days &ndash; including last Friday, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) lost 0.9 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) rose 2.8 percent. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) closed the week up almost 1.2 percent.</p> <h3>Stock Moves</h3> <p>Marijuana stocks with a market cap above $100 million that trade on&nbsp;U.S. exchanges performed as follows over the last five days:&nbsp;</p> <ul> <li><strong>22nd Century Group Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>): down 3.9 percent</li> <li><strong>Aphria Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/aphqf#OTC">APHQF</a>): down 3.7 percent</li> <li><strong>Aurora Cannabis Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acbff#OTC">ACBFF</a>): up 6.1 percent</li> <li><strong>CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): up 9.7 percent</li> <li><strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): down 8.2 percent</li> <li><strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): down 12.7 percent</li> <li><strong>Green Organic Dutchman Holdings Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgodf#OTC">TGODF</a>)<strong> </strong>up 15.4 percent</li> <li><strong>Green Thumb Industries Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) up 12.2 percent</li> <li><strong>GW Pharmaceuticals PLC- ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>): down 0.6 percent</li> <li><strong>iAnthus Capital Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ithuf#OTC">ITHUF</a>): down 5.8 percent</li> <li><strong>Medical Marijuana Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mjna#OTC">MJNA</a>) down 6.9 percent</li> <li><strong>MedMen Enterprises Inc.</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) up 11.2 percent</li> <li><strong>Scotts Miracle-Gro Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>): up 0.5 percent</li> <li><strong>THC Biomed Intl Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/thcbf#OTC">THCBF</a>): down 2.9 percent</li> <li><strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>): up 38.2 percent</li> <li><strong>Zynerba Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>): down 7.2 percent</li> </ul> <h3>In Other News</h3> <p>Adolphus A. Busch V, a descendant of the late founder of Anheuser Busch, now <strong>Anheuser Busch Inbev NV (ADR) </strong>(NYSE: <a class="ticker" ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12358350/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ABV Cannabis Company ACBFF Adolphus A. Busch AMCX AMZN APHQF Beard Bros. Pharms Brightfield Group BUD Cannabis Cannabis ETF cannabis news Cannabis Stock Index cannabis stocks cannabisMD CBD CGC Chris Jeffery CNTTF CRON Debra Borchardt DISCA Drake Sutton-Shearer Elon Musk FSDDF Green Flower Green Market Report GTBIF GWPH Heavy Hitters Hemp HMLSF invest in marijuana ITHUF Jeff Siegel Joe Rogan Leaf Logix Leafly marijuana Marijuana ETF Marijuana Index Marijuana Money marijuana news marijuana stocks MEDFF Michael Klein MJ MJNA MMNFF New Frontier Data News North American Marijuana Index NXTTF Politico Pot Stocks PRØHBTD SCCYF SMG SPY Steven Gold TGODF THCBF The Daily Leaf TLRY TSLA United States Marijuana Index VIA XXII ZYNE Top Stories Markets Movers Trading Ideas Interview ETFs General SPY US78462F1030 AMZN US0231351067 DISCA US25470F1049 SMG US8101861065 VIA US92553P1021 BUD US03524A1088 CGC TSLA US88160R1014 MJNA US58463A1051 AMCX ITHUF XXII CNTTF NXTTF GWPH ZYNE THCBF ACBFF APHQF MJ MEDFF SCCYF HMLSF CRON TGODF MMNFF TLRY GTBIF FSDDF News Cannabis Top Stories Markets Movers Trading Ideas Interview ETFs General Benzinga Fri, 14 Sep 2018 21:42:34 +0000 Javier Hasse 12358350 at https://www.benzinga.com A Q&A With The Startup CEO Disrupting The Credit Bureau With Blockchain https://www.benzinga.com/markets/cryptocurrency/18/09/12358934/a-q-a-with-the-startup-ceo-disrupting-the-credit-bureau-with-b <p><em>The <a href="https://benzingafintechsummit.com/">Benzinga Fintech Summit</a> is a gathering of the top leaders in payments, lending, capital markets, blockchain and cryptocurrencies in San Francisco Nov. 14. Ahead of the Summit, Benzinga is profiling the fintech thought leaders speaking at the event.</em></p> <p>Our next installment features an interview with Spring Labs CEO Adam Jiwan, who explains how the startup is disrupting the credit bureau space with blockchain.</p> <p><strong>BZ: What is Spring Labs? What financial services problem is it solving?</strong></p> <p>AJ: Spring Labs is the company building out the Spring Protocol, a network designed to allow network participants such as financial institutions, to share information about data, such as credit and identity, without needing to share the underlying data itself. Initial use cases include ID verification, fraud mitigation&nbsp;and access to credit reporting data &mdash;&nbsp;though the protocol and network have potentially far-reaching implications and applicability.</p> <p>Those using the Spring Protocol transact with peers via our decentralized, blockchain-based network, rather than centralized entities like credit bureaus or ID verification services.&nbsp;</p> <p>Our objective is to lower overall data costs while simultaneously allowing institutions to retain full control over their data, facilitating more transparent and secure sharing than is currently possible today.</p> <p><strong>BZ: Spring Labs was born out of Avant, a leading <a href="https://www.benzinga.com/topic/fintech">fintech</a> lender &mdash; how has this positioned the company to attack the credit space?</strong></p> <p>AJ: Our relationship with Avant was &mdash; unsurprisingly &mdash; integral to the formation of Spring Labs. Since 2012, Avant has been able to serve more than 600,000&nbsp;customers, originating nearly $5 billion&nbsp;in loans. Our experiences at Avant&nbsp;and other fintech companies we helped establish really highlighted the need for significant changes to how data is processed in the financial services industry. We observed firsthand significant frictions involving security, privacy and data control in the existing centralized ecosystem for credit and identity. It is a ...</p><p><a href=https://www.benzinga.com/markets/cryptocurrency/18/09/12358934/a-q-a-with-the-startup-ceo-disrupting-the-credit-bureau-with-b alt=A Q&amp;A With The Startup CEO Disrupting The Credit Bureau With Blockchain>Full story available on Benzinga.com</a></p> Adam Jiwan Benzinga Fintech Summit Cryptocurrency Fintech News Spring Labs Events Markets Interview News Cryptocurrency Fintech Events Markets Interview Benzinga Fri, 14 Sep 2018 20:42:37 +0000 Spencer White 12358934 at https://www.benzinga.com Canadians In Marijuana Biz Could Face Lifetime US Travel Ban: What Industry Insiders Are Saying https://www.benzinga.com/markets/cannabis/18/09/12357475/canadians-in-marijuana-biz-could-face-lifetime-us-travel-ban-what-in <p>Canadians who use marijuana, work in the industry or even invest in it face a potential lifetime ban from the U.S. when trying to cross the border.&nbsp;</p> <p>That&#39;s according to a Thursday Politico&nbsp;<a href="https://www.politico.com/story/2018/09/13/canada-weed-pot-border-783260">article</a> quoting &ldquo;a senior official overseeing U.S border operations,&rdquo; Todd Owen, who explained how and why Canadians who use marijuana, work in the industry or even invest in it, face a potential lifetime ban to the U.S. when trying to cross the border.</p> <p>It doesn&rsquo;t matter that recreational cannabis is on the precicipe of&nbsp;<a href="https://www.benzinga.com/government/18/06/11911059/canada-legalizes-recreational-marijuana-nationwide-beginning-oct-17-expert">federal legality</a> in Canada; it doesn&rsquo;t matter that the&nbsp;businesses operate under the law; it doesn&rsquo;t even matter that some of the companies in question, like <strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>), <strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) or <strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) trade on major U.S. stock exchanges, the official said. Cannabis remains a Schedule I substance in the U.S.&nbsp;</p> <h3>Stocks On The Move</h3> <p>Thursday afternoon saw a few cannabis stocks plummet on the news.</p> <p>Canopy Growth, which tumbled late Thursday and early Friday, is already up&nbsp;almost 4 percent since Thursday&rsquo;s close, and more than 12 percent since the open Friday.&nbsp;</p> <p>Similarly, Cronos Group&nbsp;rebounded 0.6 ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12357475/canadians-in-marijuana-biz-could-face-lifetime-us-travel-ban-what-in alt=Canadians In Marijuana Biz Could Face Lifetime US Travel Ban: What Industry Insiders Are Saying>Full story available on Benzinga.com</a></p> 420 investor Alan Brochstein best marijuana stocks Bluebird Botanicals Canabis Canada Cannabis Canada Marijuana Cannabis cannabis news cannabis oil cannabis stocks CGC CRON ELLO Evan Eneman Ganja GTBIF HMLSF Hypur invest in marijuana is marijuana legal marijuana legal weed Luiza Ch. Savage Marc Emery marihuana marijuana marijuana dispensary marijuana laws marijuana legalization marijuana legalize marijuana news marijuana states marijuana stocks marijuanas stock med marijuana medical medical cannabis medical marijuana medical marijuana stock medicinal marijuana Michael Harinen MJ MMNFF News Politico pot Recreational Marijuana smoke weed smoking weed THC TLRY Todd Owen Tyler Beuerlein weed weed legalization weed news weed plant weed stock Markets Media Interview General CGC MJ HMLSF CRON MMNFF TLRY GTBIF News Cannabis Markets Media Interview General Benzinga Fri, 14 Sep 2018 18:03:57 +0000 Javier Hasse 12357475 at https://www.benzinga.com 5 Questions With Cannabis Retailer MedMen https://www.benzinga.com/markets/cannabis/18/09/12352414/5-questions-with-cannabis-retailer-medmen <p>Just two years after the launch of their first store in West Hollywood, <strong>MedMen Enterprices Inc.</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) has positioned itself as one of the leading cannabis retailers in the country.</p> <p>Today, the Los Angeles-based company&mdash;which IPO&rsquo;d on the Toronto Stock Exchange in May&mdash;has 19 licensed facilities across California, New York, Nevada and Florida. According to the company, MedMen stores accounted for 6 percent of all retail sales in California last year despite operating only 2 percent of stores in the state, and their flagship store is on pace to bring in $20 million in sales this year.</p> <p>They also recently closed an acquisition of Treadwell Nursery for $53 million, which will give MedMen the right to open up to 30 retail locations in the third-largest market.</p> <p>So clearly, it&rsquo;s been a big year for the company that&rsquo;s described itself as the <strong>Target Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgt#NYSE">TGT</a>) of weed. Benzinga caught up with Daniel Yi, MedMen&rsquo;s SVP of Corporate Communications and Investor Relations, to ask him a few questions.</p> <p><strong>Benzinga</strong>: First of all, explain MedMen&rsquo;s business model.</p> <p><strong>Daniel Yi:</strong> We operate as a vertically integrated cannabis infrastructure in state-sanctioned cannabis markets in the US. So we have cultivation, manufacturing, distribution and retail in every market we operate in, with an emphasis on retail. The reason we put a lot of marketing dollars and resources into putting stores in prime locations like 5th Avenue in Manhattan is because we look at this as a consumer product.</p> <p>Our theory is that medical markets eventually lead to adult use markets. If you look at the progression of every state, it goes decriminalization, medical use with varying degrees of restrictions...and then once the state and communities feel comfortable with the idea of marijuana being more legal, then you have conversations about legalizing for adult use. That&rsquo;s been the pattern for every state since California first legalized medical marijuana use in 1996.</p> <p>So our business model, our bet about 4-5 years ago, was that this industry is going to be very similar in the way it&rsquo;s regulated to the gaming industry. Every state has different rules, there&rsquo;s an overarching sanction, and sometimes there are different ordinances all the way down to the city level. But you have to understand the complexity of the ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12352414/5-questions-with-cannabis-retailer-medmen alt=5 Questions With Cannabis Retailer MedMen>Full story available on Benzinga.com</a></p> Cannabis JWN MMNFF SBUX TGT WMT Markets Interview SBUX US8552441094 JWN US6556641008 TGT US87612E1064 WMT US9311421039 MMNFF Cannabis Markets Interview Benzinga Thu, 13 Sep 2018 19:48:10 +0000 Spencer Israel 12352414 at https://www.benzinga.com Top West Coast VC On A Maturing Fintech Space: 'We're In The Very Early Innings Of Fintech Disruption' https://www.benzinga.com/fintech/18/09/12346485/top-west-coast-vc-on-a-maturing-fintech-space-were-in-the-very-early-innings- <p><em>The <a href="https://benzingafintechsummit.com/">Benzinga Fintech Summit </a>is a gathering of the top leaders in payments, lending, capital markets, blockchain and cryptocurrencies in San Francisco Nov.&nbsp;14. Ahead of the Summit, Benzinga is profiling the fintech thought leaders speaking at the event.</em></p> <p>This first installment features an interview with a leading <a href="https://www.benzinga.com/topic/fintech">fintech</a> venture capitalist: Canaan Partners&rsquo; West Coast Partner Michael Gilroy.</p> <p><strong>BZ: Tell us about your background and current role in fintech.</strong></p> <p>My career started on Wall Street as an investment banker. I advised companies on private capital fundraises and M&amp;A. That background has allowed me to have a deep understanding of the long-term financial feasibility of business models when evaluating businesses at the early stage. At Canaan, I am an investor and board member for companies across enterprise software and fintech.</p> <p><strong>BZ: What trend in fintech are you paying the most attention to right now?</strong></p> <p>The biggest trend in fintech right now is that all big brands are finally becoming fintechs. This is a trend that we&rsquo;ve seen widely across Asia &mdash; with&nbsp;Ant Financial, Grab Financial and others &mdash; and we&rsquo;re starting to ...</p><p><a href=https://www.benzinga.com/fintech/18/09/12346485/top-west-coast-vc-on-a-maturing-fintech-space-were-in-the-very-early-innings- alt=Top West Coast VC On A Maturing Fintech Space: &#039;We&#039;re In The Very Early Innings Of Fintech Disruption&#039;>Full story available on Benzinga.com</a></p> Benzinga Fintech Summit Canaan Partners Fintech News Events Interview News Fintech Events Interview Benzinga Wed, 12 Sep 2018 21:50:15 +0000 Spencer White 12346485 at https://www.benzinga.com 2 Stocks That Could Benefit From Marijuana Legalization In Michigan https://www.benzinga.com/markets/cannabis/18/09/12331408/2-stocks-that-could-benefit-from-marijuana-legalization-in-michigan <p>On Nov.&nbsp;6, 2018, Michigan voters will decide whether the Wolverine State will legalize adult-use cannabis.</p> <p>The proposal, dubbed the &ldquo;Michigan Marijuana Legalization Initiative,&rdquo; would allow adults over the age of 21 to possess, consume and grow cannabis.&nbsp;</p> <p>Michigan already has a medical cannabis program in place, which, according to the <a href="https://mjbizdaily.com/potential-325-million-425-million-michigan-medical-marijuana-market-braces-for-more-turmoil/">MJBiz Daily factbook</a>, will see sales as high as $425 million this year alone. The factbook also notes that Michigan has the country&#39;s second-largest patient base.&nbsp;</p> <p><em>Make no mistake: There are a lot of investors who are very excited about legalization in Michigan. </em></p> <p>Between a vibrant existing medical cannabis market&nbsp;and an adult-use market that could be approved in less than two months, there&rsquo;s a lot of big money flowing into Michigan right now.&nbsp;Yet investors looking to get a piece of this action won&rsquo;t have many options.</p> <p><em>Related Link: <a href="http://www.benzinga.com/markets/cannabis/18/09/12324371/david-crosby-launches-exploratory-weed-brand-predicts-cbd-will-becom"title="David Crosby Launches Exploratory Weed Brand, Predicts CBD Will Become &#039;A Hugely Successful Painkiller&#039;">David Crosby Launches Exploratory Weed Brand, Predicts CBD Will Become &#39;A Hugely Successful Painkiller&#39;</a></em></p> <p>Michigan has disclosure rules that essentially preclude public ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12331408/2-stocks-that-could-benefit-from-marijuana-legalization-in-michigan alt=2 Stocks That Could Benefit From Marijuana Legalization In Michigan>Full story available on Benzinga.com</a></p> Alan Brochstein best marijuana stocks Canabis Cannabis cannabis news cannabis oil cannabis stocks Ganja Green Chip Stocks GTBIF Hemp HMLSF IIPR invest in marijuana is marijuana KSHB legal marijuana legal weed Long Ideas marihuana marijuana marijuana dispensary marijuana laws marijuana legalization marijuana legalize marijuana news marijuana states marijuana stocks marijuanas stock med marijuana medical medical cannabis medical marijuana medical marijuana stock medicinal marijuana Michigan cannabis Michigan Marijuana Michigan Pot Michigan weed MJ MRMD News pot Recreational Marijuana smoke weed smoking weed THC weed weed legalization weed news weed plant weed stock Markets Trading Ideas Interview General KSHB MJ IIPR MRMD HMLSF GTBIF Long Ideas News Cannabis Markets Trading Ideas Interview General Benzinga Tue, 11 Sep 2018 20:46:18 +0000 Jeff Siegel 12331408 at https://www.benzinga.com Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/markets/cannabis/18/09/12324356/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we <p>A four-day week&nbsp;shortened by Labor Day still brought substantial news in the cannabis sector.&nbsp;</p> <p>&ldquo;Even though this week was a shortened trading week, there were still lots of financial deals happening. Cronos Group agreed to a partnership with Gingko Bioworks that could be worth $122 million. They are looking to Gingko to help them maximize the cannabinoid products they have created. The potential here is huge,&rdquo; Green Market Report CEO Debra Borchardt told Benzinga.</p> <p>&ldquo;On the private side, MedReleaf founders have moved on to build the Flowr Corp.&nbsp;and maybe the can repeat the same success they had with MedReleaf. I expect this RTO will be very popular due to the pedigree of these executives.&rdquo;</p> <p>Find all the details about these transactions below.</p> <p>On a more general note, Cynthia Salarizadeh, managing partner at KCSA Strategic Communications and founder of AxisWire, said: &ldquo;We have recently seen a surge in cannabis stocks, which is a great indicator for the maturity and momentum of the industry. Some of the reasons that these stocks are enjoying such a growth include the massive $4-billion dollar investment by Constellation Brands into Canopy Growth and the general&nbsp;excitement and foresight of Canada getting ready to implement their full recreational market in October.&quot;</p> <p>The developments have given investors confidence, Salarizadeh said, adding that she expects the markets will continue to reflect advancements in the cannabis sector.&nbsp;</p> <h3>Marijuana Indexes &amp; ETFs</h3> <p>The <strong>United States Marijuana Index, </strong>which tracks 18 of the largest marijuana stocks in the U.S., lost roughly 4.4 percent since Tuesday, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, ended the week almost flat &mdash;&nbsp;just $1 above its opening price Tuesday.</p> <p>Over the last five trading days, including last Friday, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) gained 5.3 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) rose 3.9 percent. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) closed the week down almost 1 percent.</p> <h3>Stock Moves</h3> <p>Marijuana stocks with market caps above $100 million that trade on U.S. exchanges performed as follows over the last five trading days:&nbsp;</p> <ul> <li><strong>22nd Century Group Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>): down 2.2 percent</li> <li><strong>Aphria Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/aphqf#OTC">APHQF</a>): up 20.3 percent</li> <li><strong>Aurora Cannabis Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acbff#OTC">ACBFF</a>): down 7.2 percent</li> <li><strong>CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): down 2.8 percent</li> <li><strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): up 12.1 percent</li> <li><strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): up 21.3 percent</li> <li><strong>Green Organic Dutchman Holdings Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgodf#OTC">TGODF</a>)<strong> </strong>up 11.5 percent</li> <li><strong>Green Thumb Industries Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) up 27.3 percent</li> <li><strong>GW Pharmaceuticals PLC- ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>): down 3.3 percent</li> <li><strong>iAnthus Capital Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ithuf#OTC">ITHUF</a>): up 3.4 percent</li> <li><strong>Medical Marijuana Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mjna#OTC">MJNA</a>) down 2 percent</li> <li><strong>MedMen Enterprises Inc.</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) down 0.5 percent</li> <li><strong>Scotts Miracle-Gro Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>): up 2.1 percent</li> <li><strong>THC Biomed Intl Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/thcbf#OTC">THCBF</a>): down 7.8 percent</li> <li><strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) up 19.2 percent</li> <li><strong>Zynerba Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>): down 8.9 percent</li> </ul> <h3>In Other News</h3> <p><strong>The Emerald Cup</strong>, one of the cannabis industry&rsquo;s largest and most respected events, announced its first set of headlining acts and the host of its 15<sup>th</sup>&nbsp;annual celebration. Cannabis enthusiasts will come together for a two-day f&ecirc;te hosted by&nbsp;comedian, actor, producer and marijuana rights advocate&nbsp;<strong>Doug Benson,</strong> with headlining musical acts including gypsy-punk band&nbsp;<strong>Gogol Bordello,</strong> instrumental electronic hip-hop duo&nbsp;Big Gigantic, contemporary reggae singer&nbsp;Protoje and&nbsp;Margo Price, a country singer-songwriter from Nashville.</p> <p>&ldquo;The Cup brings together a passionate group of cannabis lovers &mdash; not only to celebrate, but to learn from each other and engage in an important conversation about the industry as a whole,&rdquo; Tim Blake, the&nbsp;founder and producer of the Emerald Cup, told Benzinga.</p> <p>&ldquo;With our local event permit in place, we are moving full steam ahead to finalize a broad range of entertainment and educational presentations for our attendees, whether they be cannabis veterans or newcomers curious to learn more about the industry. The Cup has grown into an enormous celebration and cultural event, and this year we are proud to host our most diverse lineup ever.&rdquo;</p> <p><strong>Cronos Group </strong>and <strong>Ginkgo Bioworks </strong>announced a partnership to produce cultured cannabinoids.</p> <p>Ginkgo will combine its platform technology for organism design and development with Cronos&rsquo; proprietary technologies to produce a full spectrum of cannabinoids. As part of the deal, Cronos Group will issue &ldquo;a specific number of common shares in tranches subject to Ginkgo&#39;s achievement of certain production milestones.&rdquo;</p> <p>Cronos Group&nbsp;CEO <strong>Mike Gorenstein</strong> said: &ldquo;We are excited about this&nbsp;landmark partnership with Ginkgo, which leverages the expertise of both organizations to create cultured cannabinoids in a scalable and cost-effective way.&nbsp;Ginkgo has the technology and infrastructure to help us revolutionize the cannabis industry and we are thrilled to be partnering with them.&rdquo;</p> <p>In related news, cannabis financing firm <strong>Tidal Royalty Corp. </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tdryf#OTC">TDRYF</a>), founded by Paul Rosen, one of the co-founders of the company that gave birth to Cronos Group, announced an agreement with <strong>Diem Cannabis </strong>to finance the latter&rsquo;s expansion into Massachusetts. The company currently has cultivation, retail and home delivery operations in&nbsp;Oregon.</p> <p>Rosen, CEO and chairman of Tidal Royalty, told Benzinga: &ldquo;The Oregon market is highly competitive. To build a scalable, profitable business in that type of environment is not an easy feat, which is what impressed us greatly about the Diem team. We think that their team, together with Tidal Royalty&rsquo;s resources, will be very competitive in the newly regulated Massachusetts market.&rdquo;</p> <p><strong>Emily ...</strong></p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12324356/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ACBFF Anna Valent APHQF Athletes for CARE Big Gigantic Breath of Life Cannabis Cannabis ETF cannabis news Cannabis Stock Index cannabis stocks Canndescent CGC CNTTF CRON CURR Debra Borchardt Diem Cannabis Doug Benson Dustin Brandon Emerald Cup Emily Paxhia Flowr Corporation FSDDF Ginkgo Bioworks Global Cannabis Partnership Gogol Bordello Green Market Report GTBIF GWPH High Tide Ventures HMLSF invest in marijuana ITHUF JWCAF Kannatopia KSHB Kurt Akers LHSIF Margo Price marijuana Marijuana ETF Marijuana Index Marijuana Money marijuana news marijuana stocks MEDFF MediPharm Labs Mike Gorenstein MJ MJNA MMNFF News North American Marijuana Index Paul Rosen Poseidon Asset Management Pot Stocks Potlandia Protoje RMKXF Scott Greiper SMG Spinner Grow SPY TDRYF TGODF THCBF TLRY United States Marijuana Index Viridian Capital Advisors XXII ZYNE Events Markets Movers Trading Ideas Interview General SPY US78462F1030 SMG US8101861065 CGC MJNA US58463A1051 RMKXF ITHUF XXII CNTTF GWPH ZYNE THCBF ACBFF APHQF KSHB MJ CURR LHSIF MEDFF HMLSF CRON TGODF MMNFF TLRY GTBIF FSDDF TDRYF JWCAF News Cannabis Events Markets Movers Trading Ideas Interview General Benzinga Fri, 07 Sep 2018 23:13:53 +0000 Javier Hasse 12324356 at https://www.benzinga.com David Crosby Launches Exploratory Weed Brand, Predicts CBD Will Become 'A Hugely Successful Painkiller' https://www.benzinga.com/markets/cannabis/18/09/12324371/david-crosby-launches-exploratory-weed-brand-predicts-cbd-will-becom <p>As perhaps the world&rsquo;s most identifiable hippie, David Crosby says&nbsp;his face belongs on a package of <a href="https://www.benzinga.com/topic/cannabis">pot</a>.</p> <p>The 77-year-old singer-songwriter is pursuing a cannabis licensing opportunity under the working name &ldquo;Mighty Croz.&rdquo;</p> <p>&ldquo;My face, my mustache, my balding head and my white hair have been on all these records for 50 god---- years, so I&rsquo;m hugely recognizable; more so even than I am famous,&rdquo; the co-founder of Crosby, Stills, Nash &amp; Young and The Byrds tells&nbsp;Benzinga.</p> <p>The number of people who recognize Crosby far exceeds the number who can name the bands he played in, he says.</p> <p>&ldquo;I figure, why not put that on the front of &nbsp;a pot package? If you&rsquo;re walking into a dispensary and you see my face smiling up at you, you&rsquo;re likely to try it. And that&rsquo;s a good thing.&rdquo;</p> <h3>A Lifelong Relationship With Weed&nbsp;</h3> <p>Crosby&rsquo;s career is shrouded in pot smoke, from songs like &ldquo;Eight Miles High,&rdquo; &ldquo;Wooden Ships&rdquo; and &ldquo;Almost Cut My Hair&rdquo; to ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/09/12324371/david-crosby-launches-exploratory-weed-brand-predicts-cbd-will-becom alt=David Crosby Launches Exploratory Weed Brand, Predicts CBD Will Become &#039;A Hugely Successful Painkiller&#039;>Full story available on Benzinga.com</a></p> cannabidiol Cannabis CBD Crosby David Crosby HMLSF marijuana medical marijuana MJ Nash & Young Recreational Marijuana Stills Stills & Nash The Byrds Top Stories Markets Interview MJ HMLSF Cannabis Top Stories Markets Interview Benzinga Fri, 07 Sep 2018 21:06:46 +0000 Javier Hasse 12324371 at https://www.benzinga.com Even Marijuana Bulls Are Becoming Skeptical Of US-Listed Cannabis Stock Prices https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12309281/even-marijuana-bulls-are-becoming-skeptical-of-us-liste <p>Cannabis stocks were again smoking Wednesday after <strong>Cronos Group Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) announced a partnership with Ginkgo Bioworks before to produce cannabinoids at scale.</p> <p>Analysts are optimistic about the future for the marijuana industry, but even cannabis bulls are increasingly skeptical of market valuations after yet another big day of gains in weed stocks.</p> <h3>More Good News</h3> <p>Cannabinoids are the molecules in marijuana that impact the human brain, including THC and CBD.</p> <p>&ldquo;The potential uses of cannabinoids are vast, but the key to successfully bringing cannabinoid-based products to market is in creating reliable, consistent, and scalable production of a full spectrum of cannabinoids, not just THC and CBD,&rdquo; Cronos Chief Executive Mike Gorenstein said in <a href="https://www.marketwatch.com/story/highflying-pot-stocks-gain-more-altitude-after-cronos-details-landmark-partnership-2018-09-04">a statement</a>.</p> <p><strong>Tilray Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) traded higher by 18.1 percent and <strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) traded higher by 2.7 percent on Wednesday.</p> <h3>Brochstein&rsquo;s Take</h3> <p>New Cannabis Ventures founding partner and <a href="https://marketfy.com/product/420investor/blog/815/">420 Investor</a> author Alan Brochstein joined Benzinga&#39;s <a href="https://soundcloud.com/bztv/premarket-prep-for-september-5-crazy-pot-stock-valuations-and-tech-testimonies">PreMarket Prep</a> show Wednesday to discuss the valuations of marijuana stocks and the implications of the latest news.</p> <p>Marijuana stocks are getting ahead of themselves, he said.</p> <p>&ldquo;I&rsquo;ve been kind of amazed by this. If you would have told me that Tilray was going to be testing $80, $90 or ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/09/12309281/even-marijuana-bulls-are-becoming-skeptical-of-us-liste alt=Even Marijuana Bulls Are Becoming Skeptical Of US-Listed Cannabis Stock Prices>Full story available on Benzinga.com</a></p> 420 investor Alan Brochstein Analyst Color Andrew Left Cannabis CGC Citron Citron Research CRON New Cannabis Ventures PreMarket Prep Short Sellers TLRY Top Stories Exclusives Markets Analyst Ratings Media Interview CGC CRON TLRY Analyst Color Short Sellers Cannabis Top Stories Exclusives Markets Analyst Ratings Media Interview Benzinga Wed, 05 Sep 2018 19:01:28 +0000 Wayne Duggan 12309281 at https://www.benzinga.com The Story Of Jack Wu: From 'Transformers' Fan To Robot Creator https://www.benzinga.com/news/18/09/12265663/the-story-of-jack-wu-from-transformers-fan-to-robot-creator <p>Jack Wu is the co-founder and CEO of a robotic aerial security company: <strong>Nightingale Security. </strong>He grew up in a military family and, while other kids were watching cartoons, his dad had him watch military documentaries with him &ndash; because they only had one TV.</p> <p>&ldquo;My passion for military strategy and equipment led me to discover the importance of surveillance technologies. That understanding, combined with my deep interest in robotics, was the genesis of Nightingale Security,&rdquo; Wu told Benzinga in a recent interview.</p> <h3>Meet Nightingale</h3> <p>&ldquo;Nightingale is the leader in Robotic Aerial Security - using intelligent software and continuous learning to autonomously protect large, remote and valuable assets for Fortune 500 corporations,&rdquo; Wu explained. He likes to define Nightingale&rsquo;s business model as a RaaS model: Robot-as-a-Service. It&rsquo;s similar to <strong>Oracle Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>)&rsquo;s SaaS business, which combines its hardware platform with software, to provide a subscription-based enterprise solution.</p> <p>&ldquo;We are building a market leading RaaS business with room for future expansion into other enterprise drone applications,&rdquo; Wu said.</p> <p>&ldquo;My foray into ...</p><p><a href=https://www.benzinga.com/news/18/09/12265663/the-story-of-jack-wu-from-transformers-fan-to-robot-creator alt=The Story Of Jack Wu: From &#039;Transformers&#039; Fan To Robot Creator>Full story available on Benzinga.com</a></p> Jack Wu Nightingale Robotics Nightingale Security ORCL Robotics Transformers Entrepreneurship Top Stories Startups Exclusives Tech Interview General ORCL US68389X1054 Entrepreneurship Top Stories Startups Exclusives Tech Interview General Benzinga Tue, 04 Sep 2018 12:31:55 +0000 Javier Hasse 12265663 at https://www.benzinga.com Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week https://www.benzinga.com/markets/cannabis/18/08/12293172/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we <p>The Trump administration launched a campaign to &ldquo;counteract positive marijuana messages and identify problems with state legalization initiatives,&rdquo; BuzzFeed News reporter Dominic Holden<strong> </strong>revealed in an <a href="https://www.buzzfeednews.com/article/dominicholden/trump-secret-committee-anti-marijuana">investigative piece</a> this week.</p> <p>&ldquo;The Marijuana Policy Coordination Committee, as it&rsquo;s named in White House memos and emails, instructed 14 federal agencies and the Drug Enforcement Administration this month to submit &lsquo;data demonstrating the most significant negative trends&rsquo; about marijuana and the &lsquo;threats&rsquo; it poses to the country,&rdquo; the article reads.</p> <p>In the markets realm, &ldquo;The biggest market news this week was the launching of Charlotte&#39;s Web stock under the symbol CWEB, which was priced at C$7 [$5.35] and closed on its first day at C$9.70 [$7.40],&rdquo; Debra Borchardt, CEO of Green Market Report told Benzinga. &ldquo;The valuation of C$100 million [$76.6 million] was a little rich considering the company only had C$40 million [$30.6 million] in revenue last year.</p> <p>&ldquo;Marijuana stocks&nbsp;did face some headwinds this week when it was reported by&nbsp;<a href="http://nymag.com/daily/intelligencer/2018/08/wh-launches-initiative-to-highlight-the-evils-of-weed.html">The Daily Intelligencer</a>&nbsp;that launched a secret commission to drum up negative marijuana news,&rdquo; she added. &ldquo;Fears of a new War On Drugs worried investors who were thinking the worst was behind them. In addition to that, Citron Research issued <a href="https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12286022/cronos-group-plummets-after-citron-calls-it-the-dark-si">harsh reports</a> on CV Sciences and Cronos Group causing both of those stocks to tumble.&rdquo;</p> <p>A&nbsp;<strong>Cronos </strong>spokesperson told Benzinga,&nbsp;&quot;We are very confident in the company and the opportunities ahead of us.&nbsp;As independent industry analysts have already noted, the Citron reports is flawed, with numerous misleading and inaccurate statements. Even Citron admitted just today that it has already covered part of its short position.&nbsp;[W]e look forward to continuing to grow our business and deliver on our performance objectives.</p> <h3><strong>Marijuana Indexes &amp; ETFs</strong></h3> <p>The <strong>United States Marijuana Index, </strong>which tracks 18 of the largest marijuana stocks in the U.S., gained 2 percent this week, while the <strong>North American Marijuana Index</strong>, which also includes Canadian stocks, moved up about 0.7 percent.</p> <p>Over the last five trading days, the <strong>Horizons Marijuana Life Sciences Index ETF</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hmlsf#OTC">HMLSF</a>) (TSE:HMMJ) gained 4.75 percent, while the <strong>ETFMG Alternative Harvest ETF </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mj#NYSE">MJ</a>) rose 3.4 percent. The <strong>SPDR S&amp;P 500 ETF Trust </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spy#NYSE">SPY</a>) closed the week up 0.9 percent.</p> <h3><strong>Stock Moves</strong></h3> <p>Here are some of the top marijuana stocks (market cap above $100 million) in U.S. exchanges and how the performed over the last five trading days:</p> <ul> <li><strong>22nd Century Group Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xxii#NYSE">XXII</a>): up 8 percent</li> <li><strong>Aphria Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/aphqf#OTC">APHQF</a>): up 18.5 percent</li> <li><strong>Aurora Cannabis Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/acbff#OTC">ACBFF</a>): up 1 percent</li> <li><strong>CannTrust Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/cnttf#OTC">CNTTF</a>): up 9.7 percent</li> <li><strong>Canopy Growth Corp </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>): up 1.4 percent</li> <li><strong>Cronos Group Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>): down 1.4 percent</li> <li><strong>Green Organic Dutchman Holdings Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/tgodf#OTC">TGODF</a>)<strong> </strong>down 2.7 percent</li> <li><strong>Green Thumb Industries Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/gtbif#OTC">GTBIF</a>) up 41.3 percent</li> <li><strong>GW Pharmaceuticals PLC- ADR </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gwph#NASDAQ">GWPH</a>): up 2.6 percent</li> <li><strong>Hiku Brands Company Ltd</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/djacf#OTC">DJACF</a>): up 2.4 percent</li> <li><strong>iAnthus Capital Holdings Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/ithuf#OTC">ITHUF</a>): up 13.5 percent</li> <li><strong>Medical Marijuana Inc </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/mjna#OTC">MJNA</a>) down 0.4 percent</li> <li><strong>MedMen Enterprises Inc.</strong> (OTC: <a class="ticker" href="https://www.benzinga.com/stock/mmnff#OTC">MMNFF</a>) up 14.2 percent</li> <li><strong>Scotts Miracle-Gro Co </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smg#NYSE">SMG</a>): up 1 percent</li> <li><strong>THC Biomed Intl Ltd </strong>(OTC: <a class="ticker" href="https://www.benzinga.com/stock/thcbf#OTC">THCBF</a>): down 2.4 percent</li> <li><strong>Tilray Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tlry#NASDAQ">TLRY</a>) up 46.9 percent</li> <li><strong>Zynerba Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zyne#NASDAQ">ZYNE</a>): up 26.3 percent</li> </ul> <h3><strong>In Other News</strong></h3> <p>Wendy Robbins and Karen Paull, creators of the critically acclaimed &ldquo;<a href="https://www.benzinga.com/news/18/08/12113454/the-shark-tank-of-cannabis-debuts-on-amazon-prime-with-millions-to-distribute">The Marijuana Show</a>,&rdquo;&nbsp;announced they will be kicking off the U.S. tour for their new cannabis-focused documentary &ldquo;Legalize It,&rdquo; with a Sept. 6 premiere in Tampa, Florida. The ladies told Benzinga they timed the tour to precede the November mid-term election, with the hopes its heavy theme would impact the outcome of hemp and cannabis initiatives across the country.</p> <p>&ldquo;The stories in this film feature kids fighting cancer, moms putting their freedom at risk to get their children cannabis-based medications, and many other moving stories,&rdquo; said Karen Paull. &ldquo;It comes to show that access to THC and CBD products is now a human rights issue.&rdquo;</p> <p><strong>Green Thumb Industries</strong> reported strong Q2 2018 earnings, its first as a publicly traded company since listing on the Canadian Securities Exchange in June.&nbsp;Second-quarter revenues increased 291 percent year-over-year to $13.6 million, while quarter-over-quarter revenues increased 25 percent.&nbsp;GTI&rsquo;s net income was $0.4 ...</p><p><a href=https://www.benzinga.com/markets/cannabis/18/08/12293172/pot-stocks-etfs-top-news-and-data-from-the-cannabis-industry-this-we alt=Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week>Full story available on Benzinga.com</a></p> ACBFF AMZN APHQF AXIM Ben Kovler Cannabis Cannabis ETF cannabis news Cannabis Stock Index cannabis stocks CGC Charlotte's Web Citron Research CNNRF CNTTF CRON CVSI Debra Borchardt Défoncé Chocolatier DJACF Dominic Holden Dustin Brandon ELLXF GemmaCert Green Market Report GTBIF GWPH HMLSF invest in marijuana ITHUF Jason Matlo Jeff Siegel Karen Paull Legalize It Leon Cooperman marijuana Marijuana ETF Marijuana Index Marijuana Money marijuana news marijuana stocks MEDFF MJ MJNA MMNFF MPXEF New Frontier Data News North American Marijuana Index PHOT Pot Stocks Potlandia Rosette Luve RVVTF Short Sellers SMG SPY Start Your Own Cannabis Business TDRYF TGODF THCBF The Marijuana Show TLRY United States Marijuana Index Weekend Unlimited Wendy Robbins XXII ZYNE After-Hours Center Markets Movers Trading Ideas Interview General SPY US78462F1030 AMZN US0231351067 SMG US8101861065 CGC MJNA US58463A1051 PHOT ITHUF XXII CNTTF CVSI GWPH ZYNE THCBF ACBFF RVVTF APHQF AXIM MJ CNNRF DJACF MPXEF MEDFF HMLSF CRON TGODF MMNFF TLRY GTBIF TDRYF ELLXF News Short Sellers Cannabis After-Hours Center Markets Movers Trading Ideas Interview General Benzinga Fri, 31 Aug 2018 20:08:16 +0000 Javier Hasse 12293172 at https://www.benzinga.com Cronos Group, Analyst Respond To Citron's Short Report https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12292756/cronos-group-analyst-respond-to-citrons-short-report <p><strong>Cronos Group Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cron#NASDAQ">CRON</a>) stock bounced back by 8.8 percent Friday after a 30-percent Thursday sell-off. The decline stemmed from <a href="http://www.benzinga.com/analyst-ratings/analyst-color/18/08/12286022/cronos-group-plummets-after-citron-calls-it-the-dark-si">accusations from Citron Research</a> that Cronos is deceiving investors by not disclosing the size of its distribution agreements with Canadian provinces.</p> <h3>Citron&rsquo;s Take</h3> <p>Citron&#39;s Andrew Left said Thursday morning that Cronos&rsquo; agreements are so small that they wouldn&rsquo;t even come close to justifying the huge gains in the company&rsquo;s market cap. Left said Cronos lags its Canadian cannabis peers in sales, trades at a steep premium to <strong>Canopy Growth Corp</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) (which has a beverage deal in place), has a history of product recalls, has no U.S. business and is spending practically nothing on research and development.</p> <p>&ldquo;When looking at Cronos relative to other cannabis stocks that have yet to receive a &lsquo;beverage deal,&rsquo; Cronos&rsquo; ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/18/08/12292756/cronos-group-analyst-respond-to-citrons-short-report alt=Cronos Group, Analyst Respond To Citron&#039;s Short Report>Full story available on Benzinga.com</a></p> Analyst Color Andrew Left Cannabis CGC Citron Citron Research CRON GMP Martin Landry Short Sellers STZ Price Target Top Stories Exclusives Markets Analyst Ratings Interview STZ US21036P1084 CGC CRON Analyst Color Short Sellers Cannabis Price Target Top Stories Exclusives Markets Analyst Ratings Interview Benzinga Fri, 31 Aug 2018 18:55:06 +0000 Wayne Duggan 12292756 at https://www.benzinga.com